Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Tokyo, Japan.
Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Immun Inflamm Dis. 2020 Dec;8(4):650-658. doi: 10.1002/iid3.354. Epub 2020 Sep 23.
The aim of this study is to evaluate the relationship between chronic endometritis (CE) and a personalized window of implantation (WOI), identified by results of endometrial receptivity analysis (ERA), and pregnancy outcomes following embryo transfer (ET) based on the ERA outcomes.
The single-center, cross-sectional study was designed. The study population consisted of 101 infertile women who underwent endometrial sampling between June 2018 and February 2020. We recruited 88 patients who underwent ERA testing and immunohistochemistry of the plasma cell marker CD138 to diagnose CE within 3 months of testing. Subjects were divided into three groups as follows: 33 without CE (non-CE group); 19 with untreated CE at ERA testing (CE group); and 36 successfully treated for CE before ERA testing (cured-CE group). CE diagnosis was defined as ≥5 CD138-positive plasma cells per 10 random stromal areas at ×400 magnification.
In non-CE, CE, and cured-CE groups, the numbers of CD138-positive cells were 0.7 ± 1.0, 28.5 ± 30.4, and 1.3 ± 1.3, respectively (p < .001). The rates of "receptive" endometrium in non-CE and cured-CE groups were 57.6% (19 women) and 50.0% (18 women), respectively; however, in the CE group, this rate was significantly lower than the other two groups (p = .009) at only 15.8% (3 women). After CE were treated prior or posterior to the ERA test in cured-CE or CE groups, the clinical pregnancy rates at the first ET in non-CE, CE, and cured-CE groups were 77.8% (21/27 cycles), 22.2% (4/18 cycles), and 51.7% (15/29 cycles), respectively (p < 0.001).
CE had detrimental effects on the individual WOI, leading to embryo-endometrial asynchrony; therefore, diagnosis and treatment of CE should be done before ERA testing.
本研究旨在评估慢性子宫内膜炎(CE)与子宫内膜容受性分析(ERA)结果确定的个体化种植窗(WOI)之间的关系,并评估基于 ERA 结果的胚胎移植(ET)后妊娠结局。
本单中心、横断面研究设计。研究人群包括 2018 年 6 月至 2020 年 2 月期间进行子宫内膜取样的 101 名不孕女性。我们招募了 88 名在 ERA 检测和浆细胞标志物 CD138 的免疫组织化学检测中进行 CE 诊断的患者,这些患者在检测后 3 个月内接受了 ERA 检测。受试者分为三组:33 名无 CE(非 CE 组);19 名在 ERA 检测时未经治疗的 CE(CE 组);和 36 名在 ERA 检测前成功治疗 CE(治愈 CE 组)。CE 诊断定义为在 ×400 放大倍数下,每 10 个随机基质区域中≥5 个 CD138 阳性浆细胞。
在非 CE、CE 和治愈 CE 组中,CD138 阳性细胞的数量分别为 0.7±1.0、28.5±30.4 和 1.3±1.3(p<0.001)。非 CE 和治愈 CE 组的“容受性”子宫内膜率分别为 57.6%(19 名女性)和 50.0%(18 名女性);然而,在 CE 组中,这一比例明显低于其他两组(p=0.009),仅为 15.8%(3 名女性)。在治愈 CE 组或 CE 组中,在 ERA 检测前或后治疗 CE 后,非 CE、CE 和治愈 CE 组的首次 ET 临床妊娠率分别为 77.8%(21/27 个周期)、22.2%(4/18 个周期)和 51.7%(15/29 个周期)(p<0.001)。
CE 对个体 WOI 有不利影响,导致胚胎-子宫内膜不同步;因此,应在 ERA 检测前诊断和治疗 CE。